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ABSTRACT
Introduction The primary aim of this study is to compare 
the efficacy of three short-term glucose-lowering 
interventions (exercise, metformin and dapagliflozin) on 
glycaemic variability in overweight or obese men and 
women with elevated diabetes risk (ie, prediabetes, defined 
as haemoglobin A
1c (HbA1c)39–47 mmol/mol / 5.7%–6.4%). 
The secondary aims are to investigate the effects of the 
interventions on body composition and cardiometabolic risk 
factors.
Methods and analysis The Pre-D Trial is an investigator-
initiated, randomised, controlled, parallel, open-label, 
superiority trial. The study aims to assign 120 participants in a 
1:1:1:1 ratio to receive one of four interventions for 13 weeks: 
(1) dapagliflozin (10 mg once daily); (2) metformin (850 mg 
twice daily); (3) exercise (interval training, 
 5 days a week, 30 min per session); or (4) control (lifestyle 
advice). After the 13 weeks of intervention, a follow-up period 
of 13 weeks will follow to study the long-term effects of 
the interventions. The primary endpoint is reduction from 
baseline to end-of treatment (13 weeks) in mean amplitude 
of glycaemic excursions measured by continuous glucose 
monitoring. The secondary endpoints include concomitant 
changes in various measures of glucose metabolism, body 
weight, cardiorespiratory fitness, blood pressure, plasma lipids, 
objectively measured physical activity and dietary intake.
Ethics and dissemination The study protocol has been 
approved by the Ethics Committee of the Capital Region and 
the Danish Medicines Agency. Approval of data and biobank 
storage has been obtained from the Danish Data Protection 
Board. The study will be carried out according to the 
Declaration of Helsinki and to the regulations for good clinical 
practice. The results from this trial will allow a number of 
research questions concerning the effect of exercise versus 
dapagliflozin or metformin in HbA
1c-defined prediabetes to be 
addressed.
Trial registration NCT02695810
IntroductIon
Individuals with prediabetes are at high risk of 
developing type 2 diabetes and cardiovascular 
disease.1 2 The Diabetes Prevention Program 
showed that lifestyle modification is more 
effective than metformin in lowering diabetes 
incidence when diabetes is diagnosed by 
an oral glucose tolerance test (OGTT).3 
However, the superiority of lifestyle interven-
tion over metformin is less clear when type 
2 diabetes is diagnosed by haemoglobin A1c 
(HbA1c).
4 This indicates that findings from 
individuals diagnosed by an OGTT cannot be 
directly transferred to individuals diagnosed 
by HbA1c.
The reason for the different effects of phys-
ical activity and metformin in individuals 
identified by OGTT versus HbA1c may be 
related to differences in the relative contri-
butions of insulin resistance and beta cell 
dysfunction associated with the different 
diagnostic criteria. Fasting hyperglycaemia 
is mainly caused by impaired first-phase 
insulin secretion and insulin resistance in the 
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Protocol
Strengths and limitations of this study
 ► First randomised controlled trial testing the 
effect of  sodium-glucose cotransporter 2  (SGLT2) 
inhibition in individuals with prediabetes defined 
by haemoglobin A
1c.
 ► Head-to-head comparison of metformin, 
SGLT2  inhibitors and exercise on glycaemic 
variability in prediabetes.
 ► Detailed physiological examinations allowing 
investigation of energy expenditure and substrate 
oxidation patterns.
 ► The study may have limited statistical power to 
show interindividual differences in treatment 
responsiveness within each treatment arm 
(subgroup analyses).
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liver, whereas hyperglycaemia 2 hours after oral glucose 
ingestion is related to whole body insulin resistance and 
reduced second-phase insulin secretion.5 6 In general, 
prediabetes or type 2 diabetes diagnosed by HbA1c is 
characterised by a combination of the defects observed 
in individuals with fasting versus 2-hour hyperglycaemia,7 
but large differences exist between cohorts.8 9
HbA1c reflects the mean glucose concentration during 
the past 8–12 weeks. It is well documented that high HbA1c 
levels are associated with an increased risk of diabetic 
complications.1 However, daily glucose fluctuations (ie, 
glycaemic variability) may be even more important than 
sustained hyperglycaemia in terms of the risk of devel-
oping diabetic complications.10 Studies have shown that 
glucose fluctuations increase the risk for endothelial 
dysfunction, retinopathy and coronary artery disease 
independent of the level of mean glycaemia.11–15 Also, 
increased use of multiple daily insulin injections and 
insulin pump therapy, which reduce glycaemic variability, 
has been associated with a reduced risk of retinopathy.16 
Together, these findings suggest that reducing glucose 
fluctuations and not only mean glycaemia is a highly rele-
vant focus for future diabetes-related trials.17
An often used measure of glycaemic variability is the 
mean amplitude of glycaemic excursions (MAGE), which 
reflects the mean of the differences between consecu-
tive peaks and nadirs in blood glucose concentrations, 
and thereby is independent of the mean glucose level.15 
MAGE is associated with coronary artery disease, vascular 
endothelial function and oxidative stress independent 
of HbA1c and fasting plasma glucose levels.
11–14 Different 
interventions are expected to have different effects 
on mean, fasting and postprandial glucose concentra-
tions, as well as on MAGE. Exercise is known to reduce 
the postprandial glucose response18–21 and thereby will 
reduce MAGE.22 It is recommended that patients with 
type 2 diabetes as well as persons with prediabetes should 
perform at least 150 min of moderate-to-vigorous inten-
sity aerobic exercise per week.23 A recent study in adults 
with a high risk of type 2 diabetes suggests that to obtain 
an improvement in glycaemic control, exercise should be 
performed in sessions with high intensities as compared 
with sessions with a longer duration with lower intensi-
ties (same total energy expenditure).24 In line with this, 
several studies suggest that interval training has a favour-
able effect on glycaemic control and glycaemic variability 
in persons with or at high risk of type 2 diabetes and can 
be performed with a high compliance.25–29
In contrast to exercise, the actions of metformin 
are predominantly on hepatic insulin sensitisation 
and inhibition of gluconeogenesis. Metformin will 
therefore preferentially lower fasting glucose concen-
trations3 30–34 and is not likely to have the same 
beneficial effects on MAGE as exercise. Sodium-glucose 
cotransporter 2 (SGLT2) inhibitors are a relatively new 
class of medication for patients with type 2 diabetes. 
SGLT2 inhibitors block glucose reabsorption in the 
kidney if blood glucose levels exceed 9–10 mmol/L35. 
Their efficacy and safety have been studied in multiple 
randomised controlled trials of individuals with type 
2 diabetes.36–38 Treatment with SGLT2 inhibitors has 
shown to lower the renal threshold for glucose excre-
tion in a dose-dependent manner both in individuals 
with type 2 diabetes and normal glucose regulation.39 40 
In normal glucose-tolerant normal-weight to overweight 
men, SGLT2 inhibitors reduce postprandial glucose 
and insulin levels by increasing urinary glucose excre-
tion.41 However, fasting glucose levels do not seem to 
be affected by SGLT2 inhibition in non-diabetic indi-
viduals.42 Because SGLT2 inhibitors are mostly effective 
at blood glucose levels above 9–10 mmol/L35, whereas 
physical activity and exercise can reduce postpran-
dial glucose levels even in the normal and prediabetic 
glycaemic range,19 43 it is expected that the exercise 
intervention is superior to SGLT2 inhibitors in reducing 
MAGE.
To date, metformin is the only widely accepted medi-
cation for use in prediabetes.44 This trial will provide 
evidence as to whether it will be relevant to further 
examine the long-term effect of SGLT2 inhibitors on 
prevention of type 2 diabetes and cardiovascular disease 
in prediabetic individuals.
objectIves
The primary objective of this study is to compare the 
short-term (13 weeks) efficacy of three glucose-low-
ering interventions (exercise, metformin and SGLT2 
inhibition) on glycaemic variability in overweight 
or obese individuals with prediabetes defined as 
HbA1c 39–47 mmol/mol (5.7%–6.4%). The secondary 
aims are to investigate the effects of the interven-
tions on body composition and cardiometabolic risk 
factors. Third, we aim to identify subgroups of indi-
viduals who do not respond or respond better than 
others to lifestyle and pharmacological interventions, 
and to determine how daily exercise bouts and time 
spent sedentary and in moderate-to-vigorous phys-
ical activity intensities are related to measures of 
glycaemic variability, insulin sensitivity and beta cell 
function.
HypotHeses
In relation to the overall objective, the following are the 
hypotheses:
1. Exercise is superior to the pharmacological 
interventions in reducing glycaemic variability.
2. Metformin will predominantly lower fasting 
glucose levels and only have minor effects on 
postprandial glucose levels. Dapagliflozin will 
reduce glucose levels in the postprandial state, but 
not in the fasting state. Accordingly, dapagliflozin 
is superior to metformin in reducing glycaemic 
variability.
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MetHods and analysIs
study design
The study is an investigator-initiated, randomised, 
controlled, parallel, open-label trial (figure 1). A total 
of 120 participants will be randomly assigned in a 1:1:1:1 
ratio to receive one of four interventions for 13 weeks: (1) 
dapagliflozin (10 mg once daily); (2) metformin (850 mg 
twice daily); (3) exercise (interval training, 5 days a week, 
30 min per session); or (4) control (lifestyle advice). After 
the 13 weeks of intervention, a follow-up period of 13 
weeks will follow to study the longer term effects of the 
interventions.
participants
Eligible participants are overweight or obese adults who 
meet the eligibility criteria for prediabetes defined by 
HbA1c
45 (box 1). After informed consent, participants who 
meet the inclusion criteria without conditions leading to 
exclusion at the screening examination will be enrolled 
for randomisation, followed by 13 weeks of treatment 
and 13 weeks of follow-up at the Steno Diabetes Center, 
Gentofte, Denmark. Inclusion and exclusion criteria are 
listed in box 1.
eligibility criteria
Although recruitment is mainly directed at middle-aged 
overweight individuals, the age criterion was set at ≥30 
years to include groups at high risk for prediabetes in 
early adulthood, such as young women with a history of 
gestational diabetes. An upper age limit of 70 years is set 
because the ability to reduce the risk or postpone the 
development of diabetes and cardiovascular disease is 
expected to be limited in individuals above 70 years of 
age. The body mass index (BMI) criterion of ≥25 kg/m2 
is used in order to identify individuals with a high risk 
of having prediabetes, thereby limiting the number of 
screen failures.
Most exclusion criteria are chosen to reduce the risk 
of adverse effects related to the interventions. Individuals 
with clinically significant cardiovascular or pulmonary 
diseases are excluded because the examinations require 
performing cardiorespiratory fitness tests and the exer-
cise intervention requires performing interval training in 
alternating high and low intensities. Also individuals with 
injuries or disabilities that make them unable to perform 
the interval training are excluded. At the screening, 
all participants will be asked about their motivation to 
participate in the trial if they are randomised to exercise, 
Figure 1 Design of the randomised controlled trial.
Box 1 Inclusion and exclusion criteria
Inclusion criteria
 ► Prediabetes (haemoglobin A1c 39–47 mmol/mol/5.7%–6.4%)
 ► ≥30 to ≤70 years of age
 ► BMI ≥25 kg/m2
 
Exclusion criteria
 ► Uncontrolled medical issues including but not limited to 
cardiovascular pulmonary, rheumatological, haematological, 
oncological, infectious, gastrointestinal or psychiatric disease; 
diabetes or other endocrine disease; immunosuppression
 ► Current treatment with hormones that affect glucose metabolism
 ► Current treatment with loop diuretics or thiazide diuretics
 ► Current treatment with beta blockers or peroral steroids
 ► Bariatric surgery within the past 2 years
 ► Impaired renal function defined as an estimated GFR<60 mL/
min/1.73 m2
 ► Neurogenic bladder disorders
 ► Alcohol/drug abuse or in treatment with disulfiram (Antabus) at time 
of inclusion
 ► Pregnant or lactating women
 ► Fertile women not using birth control agents, including oral 
contraceptives, gestagen, injection, subdermal implantation 
hormonal vaginal ring, transdermal application or intrauterine 
devices
 ► Allergic to one or more of the medications used in the study
 ► Unable to exercise according to protocol (judged by investigator 
based on the participant’s motivation, injuries/disabilities, and 
evaluation of ECG)
 ► Concomitant participation in other intervention study
 ► Unable to understand the informed consent and the study procedures
BMI, body mass index; GFR, glomerular filtration rate.
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medication or the control group in order to lower the risk 
of dropouts after randomisation.
Individuals with any degree of renal impairment are 
excluded because of their increased risk of adverse events 
with both metformin46 and dapagliflozin47 treatments. In 
addition, the efficacy of dapagliflozin on glucose reab-
sorption is limited in individuals with impaired renal 
function.47 Pregnant or nursing women as well as women 
who anticipate pregnancy during the course of the 
programme are also excluded from the study. The reason 
is that in Denmark neither metformin nor dapagliflozin is 
recommended during pregnancy or nursing. In addition, 
pregnancy modifies insulin resistance, which can affect 
the outcome measures.
Thiazide diuretics, loop diuretics and beta blockers 
are commonly used to treat hypertension, which often 
coexists with prediabetes. Dapagliflozin may add to 
the diuretic effect of thiazide and loop diuretics and 
may increase the risk of dehydration and hypotension. 
Because these agents may cause adverse events in rela-
tion to the interventions, individuals using thiazides, 
loop diuretics or beta blockers on a daily basis are ineli-
gible. However, such individuals may be included in the 
study if they meet HbA1c and other eligibility criteria 
after their treatment is changed to other antihyperten-
sive drugs without known adverse effects related to the 
interventions.
recruitment of participants
Recruitment strategies appropriate for the identified 
target population include advertisements in online 
media and newspapers, recruitment of relatives to 
patients with diabetes at Steno Diabetes Center, and 
recruitment through contact with local general practi-
tioners. Persons who show their interest in participating 
will be approached by a member of the research team 
to screen for preparticipation eligibility and explain the 
main requirements of participating in the study. Individ-
uals are considered eligible at this step if the age and BMI 
criterion is met, and written information is sent to the 
potential participant. Those who are interested in partic-
ipating after reading the material are invited to a health 
examination and screening (V0, table 1). Participants 
who are eligible after the screening are included in the 
study (V1–V4, table 1).
endpoints
Primary endpoint
The primary endpoint is changes in MAGE from baseline 
to end-of treatment (13 weeks). MAGE will be estimated 
from the 6-day sensor glucose profiles by a researcher 
blinded to the interventions. MAGE will be calculated by 
taking the arithmetic mean of the blood glucose increases 
or decreases (from blood glucose nadirs to peaks or vice 
versa) when both ascending and descending segments 
exceed the value of 1 SD of the blood glucose during a 
24-hour measurement period.15
Secondary endpoints
The secondary endpoints include changes from base-
line to mid-of-treatment (6 weeks), end-of-treatment 
(13 weeks) and follow-up (26 weeks) in the following 
parameters: HbA1c, daily time spent above different 
Table 1 Schematic overview of study visits
Visit V0 V1 V2 V3 V4
Time, days from 
intervention start
−90* −6 42 91 182
Participant-related 
information
  Informed consent X
  History X
  Inclusion/Exclusion 
criteria
X
  Clinical examination X X X X
Efficacy and safety 
outcomes
  HbA1C X X X X X
  Body weight X X X X X
  Height X
  Waist circumference X X X X
  Blood pressure X X X X
  Pregnancy test X (X) (X) (X) (X)
  Fasting blood samples X X X X
  Urine samples X X X X
  Indirect calorimetry X X X
  Oral glucose tolerance 
test
X X X
  Body fat distribution 
(DEXA)
X X X
  Fitness test X X X
  Free-living physical 
activity measurement
X X X X
  Continuous glucose 
monitoring
X X X X
  Adverse events X X X
Questionnaires
  Health and well-being X X X X
  Physical activity X X X X
  Sleep patterns X X X X
  Food diary X X X X
  Treatment satisfaction X X
Study medication, drug 
accountability
X X 
  
*The maximum allowed time from the screening (V0) to the 
baseline examination (V1) is 12 weeks (=84 days). If this is not 
possible, a new screening will be performed before including the 
participant in the study.
HbA1c, haemoglobin A1c; DEXA, dual-energy X-ray absorptiometry.
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glucose concentrations (eg, >6.1 mmol/L, >7.0 mmol/L, 
>7.8 mmol/L and >11.1 mmol/L), glucose concentrations 
during OGTT (0, 30, 60 and 120 min), Insulinogenic 
Index, Insulin Sensitivity Index, body weight, body fat 
distribution, cardiorespiratory fitness, basal energy expen-
diture, substrate oxidation patterns, time spent sedentary 
and in moderate-to-vigorous physical activity intensity, 
blood pressure, heart rate, plasma lipids, biomarkers of 
metabolic functions, number of adverse events and side 
effects, changes in dietary habits, sleep patterns, self-rated 
health and quality of life, and adherence to the different 
interventions.
study visits and examinations
No study-related procedures will take place before 
informed consent has been obtained after careful written 
and oral information to the participant about the study. 
Individuals who agree to participate in the study will be 
invited to a screening visit (V0). All examinations will 
be performed at Steno Diabetes Center. Study visits and 
examinations are summarised in table 1. The examina-
tions are described below.
Clinical examination
A clinical examination including measurement of body 
weight, waist and hip circumference, blood pressure, and 
pulse is performed at all visits. Height is only measured 
at the screening visit. Height and body weight will be 
measured with the participant wearing light indoor 
clothes and no shoes. Waist circumference is measured 
halfway between the lowest point of the costal margin and 
highest point of the iliac crest, and hip circumference is 
measured at the level of the greater femoral trochanter; 
both are measured to the nearest 0.5 cm. Measurements 
of waist and hip circumference are performed three times 
each. Blood pressure and pulse are measured with the 
participant in sitting position after a minimum 10 min of 
rest using a digital blood pressure monitor, Model UA-852 
(A&D Instruments, Oxfordshire, UK). Blood pressure 
and pulse measurements are repeated three times sepa-
rated by 2 min breaks. The mean value of the last two 
measurements is used.
Continuous glucose monitoring
A 6-day continuous glucose monitoring for assess-
ment of glycaemic variability will be performed at 
V1, V2, V3 and V4. The iPro2 Continuous Glucose 
Monitoring System (CGMS) will be used (Medtronic 
Danmark A/S, Copenhagen, Denmark). The CGMS 
sensor will be inserted in the subcutaneous adipose 
tissue on the lower part of the abdomen (under the 
umbilicus). In order to calibrate the CGMS, partic-
ipants will monitor home glucose levels before 
breakfast, before lunch, before main evening meal 
and before bedtime using a glucometer (Contour XT, 
Ascensia Diabetes Care Denmark ApS, Copenhagen, 
Denmark).
Free-living physical activity and dietary intake
Concomitant with the 6-day measurement of glycaemic 
variability, measurement of free-living physical activity 
will be performed. Free-living physical activity energy 
expenditure will be measured with accelerometers 
(Axivity AX3, Newcastle upon Tyne, UK). The partic-
ipants will wear two accelerometers (one on the thigh 
and one on the back) for 6 days. Participants will be 
instructed to send the accelerometers and the contin-
uous glucose monitor back to the investigator by 
postage after the 6 days of measurements. During the 
first 4 days of measurement of physical activity and 
continuous glucose monitoring, the participants are 
asked to register their entire intake of food and caloric 
beverages (grams per portion and time of ingestion).
Electrocardiogram
An ECG is performed at the baseline visit and at the 
visits after 13 and 26 weeks in order to screen for 
heart conditions, which may exclude participants from 
performing a maximal fitness test.
Indirect calorimetry
The respiratory exchange ratio will be measured by 
indirect calorimetry after standardised conditions, 
including >8 hours of fasting and no exercise for 48 hours. 
The measurement takes place in a quiet room, where the 
participant is placed in supine position. The respiratory 
exchange ratio is calculated from the relationship between 
oxygen consumption and carbon dioxide production and 
will be used as a measure of the relative contributions of 
carbohydrate and lipid oxidation in the basal state. The 
measurement is performed with a ventilated hood using 
a JAEGER Oxycon Pro analyser (Erich JAEGER GmbH, 
Hoechberg, Germany). Before each measurement, the 
equipment is flow-calibrated and gas-calibrated to take 
into account subtle changes in humidity, temperature 
and content of O2 and CO2 in the examination room.
Oral glucose tolerance test
The participant is instructed to fast (water is allowed) 
for 8–10 hours prior to the tests. A small venous catheter 
will be inserted in one of the participant’s arms for blood 
sampling. The participant will drink a 200 mL glucose 
solution (75 g glucose) within 1 min. Blood samples 
will be drawn at 0, 30, 60 and 120 min for assessment 
of plasma glucose, insulin, C peptide, glucagon, gluca-
gon-like peptide-1 and glucose-dependent insulinotropic 
polypeptide.
Body fat content
A dual-energy X-ray absorptiometry (DEXA) scan will be 
performed to measure body fat content. Participants will 
lie still on a table while a machine arm passes over their 
entire body, which emits a high-energy and a low-energy 
X-ray beam. By measuring the absorption of each beam 
into parts of the body, readings for bone mineral density, 
lean body mass and fat mass will be obtained.
group.bmj.com on December 12, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
6 Færch K, et al. BMJ Open 2017;0:e013802. doi:10.1136/bmjopen-2016-013802
Open Access 
Cardiorespiratory fitness
After the OGTT, a fitness test for determination of peak 
oxygen consumption (VO2peak) and peak heart rate 
(HRpeak) will be performed. The test will be performed as 
an incremental test on a cycle ergometer (Monark LC4) 
with indirect calorimetry (JAEGER Oxycon Pro analyser, 
Erich JAEGER GmbH). Study participants will be cycling 
for 6 min as a warm-up (3 min at 30 W and 3 min at 60 W 
for women; 3 min at 40 W and 3 min at 80 W for men). 
After the warm-up, the workload is increased every minute 
by 20 W for women and 25 W for men until exhaustion.
Questionnaires
Self-reported physical activity is measured using the 
recent physical activity questionnaire. This questionnaire 
assesses physical activity across four domains (domestic, 
recreational, work, commuting) over the previous 
month. Questionnaires on health and well-being, sleep 
patterns and satisfaction with the interventions will also 
be filled out at each visit at the study site. During the 
6-day CGM measurements, the study participants will be 
asked to fill in a diary describing the type and duration of 
physical activity. In addition, the participants are asked to 
weigh and register intake of meals and caloric beverages 
consumed during the first 4 days of the CGMS measure-
ment period.
Sociodemographic information
Baseline sociodemographic information, which could act 
as covariates or confounders for the tested interventions, 
will also be collected. These include age, ethnicity, civil 
status, education, occupation, health history, smoking 
status and alcohol consumption.
Interventions
Dapagliflozin
Dapagliflozin (10 mg) will be administered once daily as 
monotherapy. The product will be delivered by Gentofte 
Apotek and labelled by the investigator at Steno Diabetes 
Center. Common side effects (1%–10%) include low 
blood pressure, increased number of red blood cells, 
change in plasma lipid profile, back pain, dizziness, 
inflammation in and around the vagina, inflammation 
of the foreskin, urinary tract infection, painful urination 
and increased urine volume.
Metformin
Metformin (850 mg) will be administered twice daily as 
monotherapy (1 tablet together with breakfast, 1 tablet 
together with dinner). Titration will be performed 
according to the guidelines for patients with type 2 
diabetes (one tablet daily the first week, then two tablets 
daily for the rest of the treatment period). Metformin will 
be delivered by Gentofte Apotek and labelled by the inves-
tigator at Steno Diabetes Center. Common side effects 
(1%–10%) include decreased appetite, nausea, vomiting, 
diarrhoea, stomach pain and dysgeusia.
Exercise
The exercise intervention will consist of interval training 
5 days a week, 30 min per session, at alternating 3 min 
intervals aiming at reaching intensities of ≥75% (high) 
and ≤60% (low) of HRpeak by the end of each interval. 
If the participants experience challenges in reaching 
these intensities, they are advised to aim for at least 15% 
difference between the high and low intervals (eg, 80% 
and 65% of HRpeak). The participants can freely choose 
between walking, cycling, running or other aerobic activ-
ities, and they can do the activities outdoor or in a fitness 
centre. They will be offered membership to a local fitness 
centre for the entire intervention period. The exercise 
will be monitored, evaluating the heart rate response of 
all exercise sessions. The participants will record the heart 
rates and durations of exercise bouts using Polar V800 
(Polar Electro, Kempele, Finland). The participants will 
be asked to upload heart rate data from the Polar watches 
to the software Polar Flow on their computer twice a week. 
Computer-generated reminders are sent to the partici-
pants twice a week to ensure compliance on the upload. 
As feedback and encouragement are important factors in 
adherence,48 the investigator will provide encouraging 
feedback in the form of short written comments and 
‘likes’ to the participants twice a week after upload of data 
using the online tool ‘Polar Flow for Coach’ (Polar Electro 
Danmark ApS, Holte, Denmark). Additionally, an e-mail 
is sent out to the participants once weekly with a short 
status report on the participant’s compliance to exercise 
during the past week. In case of technical challenges 
related to the watch or heart rate monitor, the participant 
is contacted by telephone to solve the problem.
Within the first week after randomisation, the partic-
ipants are invited to an introduction to the exercise 
intervention at Steno Diabetes Center. During this intro-
duction, a thorough training on the use of heart rate 
monitor and watch will take place in order to teach the 
participants how to exercise at the alternating intensities 
and make them familiar with the technology used.
Control
At the baseline examination, the control group as well as 
the three other groups will receive oral and written infor-
mation about a healthy lifestyle and weight loss according 
to the official dietary recommendations from the Danish 
Veterinary and Food Administration.49
randomisation
For safety and practical reasons, randomisation will be 
open for both participants and investigators, but assess-
ment of the primary outcome is blinded. Randomisation 
codes have been produced by the sponsor by use of the 
web-based Clinical Trial Management System EasyTrial 
(EasyTrial ApS, Glostrup, Denmark).50 Randomisation is 
performed in blocks in order to secure an equal distribu-
tion of participants in each intervention group if the trial 
unexpectedly will be terminated before inclusion of the 
planned number of participants. Details of the size of the 
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blocks are unavailable to the investigators performing the 
examinations and allocating participants to the interven-
tions. Allocation to intervention groups will take place at 
the end of the baseline examination (at day −6) to secure 
that the investigator performs all baseline measurements 
unbiased of the allocated intervention. After the base-
line measurements and allocation, the investigator puts 
the allocated intervention into a box (metformin tablets, 
dapagliflozin tablets, a Polar watch or a carton filled 
with paper), and the box is locked with a coded lock. All 
boxes have identical looks. The participant then receives 
the box containing his/her allocated treatment regime, 
but it is not revealed for the participant what the box 
contains. Six days after the baseline examination (at day 
0), the participant will receive the code to the box by tele-
phone from the investigator. This procedure is done in 
order to secure that the 6-day baseline measurements of 
continuous glucose monitoring and physical activity are 
performed unbiased of the allocated intervention by the 
participants.
assessment of compliance
Medication
Participants receiving medication are asked to bring their 
study medication to visit 2 (6 weeks) and visit 3 (13 weeks). 
The investigator will register the number of tablets taken 
and thereby assess compliance to the medication. A 
compliance of at least 80% is considered satisfactory.
Exercise
For participants in the exercise intervention group, 
compliance is monitored online via Polar V800 (Polar 
Electro, Finland) and the online tool ‘Polar Flow for 
Coach’. Participants completing ≥80% of the training 
volume prescribed (ie, 120 min per week) and ≥80% of 
the exercise sessions prescribed (ie, four sessions per 
week) are considered to be compliant. To prevent drop-
outs, two procedures are implemented if a participant 
expresses concerns about compliance with the prescribed 
exercise intervention or if the investigators experience 
that a participant does not follow the prescribed exercise 
intervention (eg, upload of exercise sessions is lacking, 
or the duration or intensity of the exercise bouts is not in 
compliance with the protocol):
1. Maintenance of training volume: The participant is 
offered a telephone interview to identify possible 
challenges in relation to the exercise intervention, 
that is, lack of time or worries. An adjusted plan is 
made in collaboration between the investigator and 
participant with the aim of maintaining the weekly 
training volume as per protocol, for example, 
fewer sessions of exercise per week but with longer 
duration (unchanged intensity).
2. Reducing training volume: If training volume cannot 
be maintained (eg, in case of injury or other 
personal issues), up to two exercise sessions per 
week are eliminated from the programme for 
2 weeks or more if necessary.
etHIcs, safety, data ManageMent and dIsseMInatIon
This intervention study will provide important informa-
tion about the effect of exercising versus prescribing 
dapagliflozin or metformin therapy to individuals with 
prediabetic glucose levels defined by the HbA1c criteria. 
All equipment used in the study meet the requirements 
for patient safety. For the determination of body compo-
sition, DEXA scanning with a weak X-ray radiation is 
used. The radiation dose is less than 0.01 mSv, which 
corresponds to less than 1 day of normal background 
radiation. The dapagliflozin tablets contain lactose, 
which may cause discomfort in lactose-intolerant individ-
uals. Dapagliflozin and metformin are not yet registered 
for treatment of individuals with prediabetes in Denmark. 
Side effects such as low blood pressure, increased number 
of red blood cells, change in plasma lipid profile, back 
pain, dizziness, inflammation in and around the vagina, 
inflammation of the foreskin, urinary tract infection, 
painful urination, increased urine volume, decreased 
appetite, nausea, vomiting, diarrhoea, stomach pain and 
dysgeusia can be expected in some study participants. 
However, it is believed that the potential beneficial effects 
of dapagliflozin and metformin on glycaemic control will 
counterbalance the potential unfavourable effects.51 52 
The participants are covered by the Patient Compensa-
tion Association according to the Danish Act on the Right 
to Complain and Receive Compensation within the 
Health Service.
The study protocol is approved by the Ethics Committee 
of the Capital Region (H-15011398) and the Danish 
Medicines Agency (EudraCT number: 2015-001552-30). 
Approval for data storage has been obtained from the 
Danish Data Protection Board (2012-58-0004). The study 
is registered with  ClinicalTrials. gov (NCT02695810) and 
will be carried out in accordance with the Declaration of 
Helsinki II and to the regulations for good clinical prac-
tice (GCP). The unit for GCP in Copenhagen University 
Hospital will perform audit site visits in order to secure 
that the study is performed in accordance with the 
International Council for Harmonisation (ICH)-GCP 
guidelines.
The investigator is responsible for ensuring that all 
serious adverse reactions/adverse events are immediately 
reported to the sponsor, who will then notify the Ethics 
Committee of the Capital Region and the Danish Medi-
cines Agency according to the existing laws and ICH-GCP 
guidelines. In case of unexpected severe adverse reac-
tions to medication during the study, the trial will be 
discontinued. In case participants suffer harm from 
participation in this trial, they will be referred to the 
Patient Compensation Association.
The web-based Clinical Trial Management System 
EasyTrial is used for data entry and management (Easy-
Trial ApS).50 EasyTrial has been approved by the Danish 
Data Protection Board. Electronic case reports forms 
and questionnaires have been generated by the sponsor 
in EasyTrial. Fields have been programmed with accept-
able ranges for data entry. EasyTrial is also used to send 
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reminders to the participants prior to visits and to remind 
participants in the exercise intervention group to upload 
heart rate data for supervision. During the study, data 
are entered directly into the system by the investigators, 
and after study completion data will be extracted directly 
from the system by the sponsor/investigators.
Positive, negative and inconclusive study results 
will be published by the investigators in international 
peer-reviewed journals and presented at international 
conferences. Manuscripts will be written in accordance 
with the online supplementary CONSORT statement and 
the Vancouver Declaration.
statIstIcal MetHods
sample size considerations
MAGE has not previously been used as primary outcome 
in randomised controlled trials of persons with predi-
abetes. A study has shown that mean (SD) MAGE is 
significantly higher in individuals with impaired fasting 
glycaemia (IFG) and  (IGT) (2.26 (0.7) mmol/L) than 
in people with normal glucose tolerance (1.60 (0.7) 
mmol/L) despite having similar HbA1c levels (5.7 vs 
5.5%).53 Similarly, MAGE was found to be significantly 
higher (mean (SD) MAGE: 2.7 (0.4) mmol/L) in women 
with previous gestational diabetes (mean HbA1c 5.8%) 
than in weight-matched normal glucose-tolerant women 
without a history of gestational diabetes (mean (SD) 
MAGE: 1.8 (0.5) mmol/L; mean HbA1c 5.4%).
54 In addi-
tion, a Chinese study found mean (SD) MAGE to be 2.1 
(0.8) mmol/L in 23 abdominally obese men versus 1.6 
(0.5) mmol/L in 23 non-abdominally obese men with 
normal glucose regulation (p<0.05).55
Randomised controlled trials in patients with type 
2 diabetes (mean duration of diabetes ~5 years) found 
that MAGE decreased from mean (SD) 4.9 (1.0) to 3.7 
(0.9) mmol/L after treatment with metformin + sita-
gliptin (p<0.001).56 The mean (SD) decrease in MAGE 
after 15 weeks of metformin treatment in patients with 
newly diagnosed type 2 diabetes was 1.4 (1.6) mmol/L57. 
In terms of SGLT2 inhibition, a study of 15 patients with 
type 1 diabetes found a mean (95% CI) reduction of 3.8 
(1.5 to 6.1) mmol/L in MAGE after 7 days of treatment 
with dapagliflozin.58 In relation to exercise, a single bout 
of exercise has shown to decrease average blood glucose 
by ~0.9 mmol/L in patients with type 2 diabetes — also in 
those with HbA1c levels below 7%.
22 In another study of 
patients with type 2 diabetes, 2 weeks of interval walking 
reduced MAGE by 1.8 (0.5) mmol/L.29
It is expected that both mean and SD of MAGE are 
lower among individuals with prediabetes than in indi-
viduals with type 2 diabetes. With a power of 80% (alpha 
level of 0.05) in a two-sided test, a clinically meaningful 
difference in the change in MAGE over the 13-week inter-
vention of ≥0.5 mmol/L (SD: 0.6 mmol/L) between two 
groups can be found with 23 participants in each group. 
To allow for dropouts (~20%) and subgroup analyses, we 
plan to include 30 participants in each of the four study 
groups. Inclusion of participants is terminated when 120 
participants have been included. In case fewer than 120 
participants are recruited, the minimum mean differ-
ences in MAGE expected to be statistically significant are 
shown in table 2 (with different SD).
Participants who withdraw from the study will not be 
replaced. Participants who are excluded or who decide to 
stop their participation will be referred to their general 
practitioner for advice on how to manage their elevated 
diabetes risk. Data on withdrawn participants will be 
collected at the end of the study and used in the safety 
analysis if allowed by the participant.
statistical analysis
Intention-to-treat (ITT) analysis will be performed after 
the last participant has completed the last visit. In addition, 
per-protocol analyses will be made (≥80% compliance to 
the interventions). In principle, the ITT strategy requires 
a complete follow-up of all randomised participants for 
study outcomes, which may not be possible to achieve, 
and therefore the ITT analysis may give a biased esti-
mate of the treatment effect. On the other hand, the ITT 
analysis reflects treatment in clinical practice to a higher 
degree than per-protocol analyses, which only include 
people who are compliant to the interventions. In order 
to address these issues, analyses with imputation of 
missing data will be performed. Patterns of missing data 
will be investigated. It is expected that missing data will 
be ‘missing at random’ rather than ‘missing completely 
at random’, because it is assumed that dropouts may 
depend on observed outcomes or covariates but not on 
unobserved data. Subgroup analyses stratified by age, 
sex, obesity degree and prediabetic subgroup (fasting vs 
2-hour hyperglycaemia) will also be performed.
Parametric tests (general linear models) will be used to 
test differences in outcomes from baseline to follow-up. 
If model assumptions cannot be met even after loga-
rithmic transformation, non-parametric tests will be used. 
Plots of residuals versus predicted values will be used 
to judge normality. Two-sided tests will be used and p 
Table 2 Sample size calculations based on a power of 0.8 
and an alpha level of 0.05 in a two-sided test with different 
SD and mean differences in MAGE
Scenario
Mean 
difference SD
Participants needed 
in each group (n)
1 0.5 0.7 31
2 0.5 0.6 23
3 0.5 0.5 16
4 0.6 0.7 22
5 0.6 0.6 16
6 0.6 0.5 11
7 0.7 0.7 16
8 0.7 0.6 12
9 0.7 0.5 8
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values of <0.05 are considered significant. Adjustment for 
multiple testing will be performed.
dIscussIon
The guidelines from the American Diabetes Association45 
suggest that individuals with prediabetes (ie, IGT, IFG or 
HbA1c 39-47 mmol/mol / 5.7%–6.4%) should increase 
physical activity level to at least 150 min/week and lose 
body weight. In prediabetic individuals who are <60 years 
of age, have BMI >35 kg/m2 or have a history of gesta-
tional diabetes, metformin therapy should be considered. 
Furthermore, the American Diabetes Association states 
that aggressive interventions should be pursued for those 
considered at very high risk (eg, those with HbA1c > 42 
mmol/mol / 6.0%).45 However, the evidence behind 
these recommendations is predominantly based on 
individuals with IGT; evidence underlying a strategy for 
HbA1c-defined prediabetes is lacking.
Rigorous monitoring of exercise bouts using online 
technology will provide experience and may constitute 
a new way of conducting studies of real-life physical 
activity interventions. Our study will describe glycaemic 
variability and a range of metabolic parameters in predi-
abetes, giving us the opportunity to determine detailed 
characteristics of individuals at risk, potentially identifying 
new parameters for interventions or prediction of future 
diseases. In addition, the study will bring new important 
and detailed data on the use of SGLT2 inhibition at an 
early stage in a risk population where pharmaceutical 
intervention is rare. As such, the results from this trial will 
challenge current medical practice and form the basis for 
futureclinical trials focused on diabetes prevention.
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